Syndax Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.99+0.09 (+0.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Syndax Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Syndax Pharmaceuticals generated -$30.3 million of operating cash flow. That left free cash flow of -$30.3 million, a free-cash-flow margin of -41.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Syndax Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -49.36M | -42.67M | -68.01M | -60.72M | -71.85M | -84.85M | -94.17M | -84.13M | -68.06M | -72.40M | -72.47M | -51.15M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 5.00M | 4.00M | — | — | 0 | 0 | — | — | — | — | — | — |
| Stock-Based Compensation | 14.01M | 12.05M | 11.25M | 12.08M | 13.79M | 10.38M | 12.30M | 11.93M | 9.90M | 8.90M | 8.33M | 8.32M |
| Change in Working Capital | -9.93M | 160.00K | -23.04M | -21.02M | -20.11M | -7.90M | -1.24M | -17.35M | 4.72M | -4.01M | 3.91M | -8.67M |
| Operating Cash Flow | -30.27M | -50.34M | -69.49M | -70.53M | -87.80M | -95.16M | -57.39M | -62.32M | -71.64M | -83.55M | -41.35M | -44.65M |
| Investing Cash Flow | -16.91M | 38.39M | 81.58M | 72.43M | 41.89M | 94.14M | -268.97M | 86.85M | 61.75M | -99.40M | -16.29M | 40.08M |
| Financing Cash Flow | 252.77M | 7.92M | 5.92M | 6.28M | 551.00K | 930.00K | 347.43M | 3.10M | 676.00K | 2.17M | 258.48M | 1.85M |
| Net Change in Cash | 205.58M | -4.04M | 18.01M | 8.17M | -45.36M | -90.00K | 21.06M | 27.62M | -9.22M | -180.78M | 200.84M | -2.73M |
| Free Cash Flow | -30.27M | -50.34M | -69.49M | -70.53M | -87.80M | -95.16M | -57.39M | -62.32M | -71.64M | -83.55M | -41.35M | -44.65M |
This table shows 12 quarterly periods of Syndax Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SNDX's reporting calendar. What is a cash flow statement?